Generation of a canine anti-EGFR (ErbB-1) antibody for passive immunotherapy in dog cancer patients

Molecular Cancer Therapeutics

Volumn 13, Issue 7, 2014, Pages 1777-1790

  Singer, Josef ^a,c   Fazekas, Judit ^a,c,d   Wang, Wei ^f   Weichselbaumer, Marlene ^a,c   Matz, Miroslawa ^a   Mader, Alexander ^e   Steinfellner, Willibald ^e   Meitz, Sarah ^a,c   Mechtcheriakova, Diana ^a   Sobanov, Yuri ^a   Willmann, Michael ^c   Stockner, Thomas ^b   Spillner, Edzard ^g   Kunert, Renate ^e   Jensen Jarolim, Erika ^a,c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^d Fachhochschule Campus Wien   (Austria)

^e UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

^f CAPITAL MEDICAL UNIVERSITY   (China)

^g UNIVERSITY OF HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CAN225IGG ANTIBODY; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY 1; IMMUNOGLOBULIN G ANTIBODY; PROTEIN G; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN G;

ANIMAL CELL; ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER INHIBITION; CELL KILLING; CELL PROLIFERATION ASSAY; CELL VIABILITY ASSAY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL DOG; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; IN VITRO STUDY; MOLECULAR CLONING; NONHUMAN; PASSIVE IMMUNIZATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PHAGOCYTOSIS; PRECURSOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; ANIMAL; CELL GROWTH; CHEMICAL STRUCTURE; CHO CELL LINE; CIRCULAR DICHROISM; CRICETULUS; DOG; DOG DISEASES; GENETIC TRANSFECTION; HAMSTER; IMMUNOLOGY; METABOLISM; NEOPLASMS; PROCEDURES; VETERINARY;

ANIMALS; CELL GROWTH PROCESSES; CHO CELLS; CIRCULAR DICHROISM; CRICETINAE; CRICETULUS; DOG DISEASES; DOGS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; MODELS, MOLECULAR; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSFECTION;

EID: 84904177355     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0288     Document Type: Article

References (69)

1. Takashima-Uebelhoer BB, Barber LG, Zagarins SE, Procter-Gray E, Gollenberg AL, Moore AS, et al. Household chemical exposures and the risk of canine malignant lymphoma, a model for human non-Hodgkin's lymphoma. Environ Res 2012;112:171-6.
2. Rivera P, von Euler H. Molecular biological aspects on canine and human mammary tumors. Vet Pathol 2011;48:132-46.
3. Gordon I, Paoloni M, Mazcko C, Khanna C. The Comparative Oncology Trials Consortium: using spontaneously occurring cancers in dogs to inform the cancer drug development pathway. PLoS Med 2009;6:e1000161.
4. Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 2008;8:147-56. (Pubitemid 351161319)
5. Sorenmo K. Canine mammary gland tumors. Vet Clin North Am Small Anim Pract 2003;33:573-96. (Pubitemid 36798638)
6. London CA, Malpas PB, Wood-Follis SL, Boucher JF, Rusk AW, Rosenberg MP, et al. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res 2009;15:3856-65.
7. Lachowicz JL, Post GS, Brodsky E. A phase I clinical trial evaluating imatinib mesylate (Gleevec) in tumor-bearing cats. J Vet Intern Med 2005;19:860-4. (Pubitemid 41736995)
8. Bergman PJ, Camps-Palau MA, McKnight JA, Leibman NF, Craft DM, Leung C, et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine 2006;24:4582-5. (Pubitemid 44218845)
9. Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012;23:2479-516.
10. Cardoso F, Fallowfield L, Costa A, Castiglione M, Senkus E. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22(Suppl 6):vi25-30.
11. Singer J, Weichselbaumer M, Stockner T, Mechtcheriakova D, Sobanov Y, Bajna E, et al. Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting. Mol Immunol 2012;50:200-9.
12. Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato GH. Biological effects in vitro ofmonoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1983;1:511-29.
13. Eccles SA. The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology. Int J Dev Biol 2011;55:685-96.
14. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37. (Pubitemid 33674041)
15. Yarden Y, Shilo BZ. SnapShot: EGFR signaling pathway. Cell 2007;131:1018.
16. Rimawi MF, Shetty PB, Weiss HL, Schiff R, Osborne CK, Chamness GC, et al. Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer 2010;116:1234-42.
17. Yang X, Zhang X, Mortenson ED, Radkevich-Brown O, Wang Y, Fu YX. Cetuximab-mediated tumor regression depends on innate and adaptive immune responses. Mol Ther 2013;21:91-100.
18. Karagiannis P, Singer J, Hunt J, Gan SK, Rudman SM, Mechtcheriakova D, et al. Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells. Cancer Immunol Immunother 2009;58:915-30.
19. Spillner E, Plum M, Blank S, Miehe M, Singer J, Braren I. Recombinant IgE antibody engineering to target EGFR. Cancer Immunol Immunother 2012;61:1565-73.
20. Vale CL, Tierney JF, Fisher D, Adams RA, Kaplan R, Maughan TS, et al. Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis. Cancer Treat Rev 2012;38:618-25.
21. Tol J, Punt CJ. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin Ther 2010;32:437-53.
22. Harris CA, Ward RL, Dobbins TA, Drew AK, Pearson S. The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis. Ann Oncol 2011;22:1308-17.
23. Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov 2003;2:52-62. (Pubitemid 37361624)
24. Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 1997;3:2703-7. (Pubitemid 28133130)
25. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995;1:1311-8.
26. Chang C, Takayanagi A, Yoshida T, Shimizu N. Recombinant human IgG antibodies recognizing distinct extracellular domains of EGF receptor exhibit different degrees of growth inhibitory effects on human A431 cancer cells. Exp Cell Res 2013;319:1146-55.
27. Knittelfelder R, Riemer AB, Jensen-Jarolim E. Mimotope vaccination - from allergy to cancer. Expert Opin Biol Ther 2009;9:493-506.
28. You B, Chen EX. Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab. J Clin Pharmacol. 2011 Mar 11. [Epub ahead of print].
29. Kurzman ID, Shi F, Vail DM, MacEwen EG. In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells. Cancer Biother Radiopharm 1999;14:121-8. (Pubitemid 29217791)
30. Soergel SA, MacEwen EG, Vail DM, Potter DM, Sondel PM, Helfand SC. The immunotherapeutic potential of activated canine alveolar macrophages and antitumor monoclonal antibodies in metastatic canine melanoma. J Immunother 1999;22:443-53. (Pubitemid 29488763)
31. Steplewski Z, Rosales C, Jeglum KA, McDonald-Smith J. In vivo destruction of canine lymphoma mediated by murine monoclonal antibodies. In Vivo 1990;4:231-4.
32. Nariai N, Kitagawa K, Nariai K, Kosaka T, Kuwabara M, Kiuchi Y. Active-oxygen involvement in canine NK-mediated cytotoxicity. J Vet Med Sci 2000;62:457-60.
33. Griffith TS, Wiley SR, Kubin MZ, Sedger LM, Maliszewski CR, Fanger NA. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med 1999;189:1343-54.
34. Washburn B, Weigand MA, Grosse-Wilde A, Janke M, Stahl H, Rieser E, et al. TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus. J Immunol 2003;170:1814-21. (Pubitemid 36197397)
35. Dalle S, Thieblemont C, Thomas L, Dumontet C. Monoclonal antibodies in clinical oncology. Anticancer Agents Med Chem 2008;8:523-32.
36. Challacombe JM, Suhrbier A, Parsons PG, Jones B, Hampson P, Kavanagh D, et al. Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J Immunol 2006;177:8123-32. (Pubitemid 44846331)
37. Ritt MG, Wojcieszyn J, Modiano JF. Functional loss of p21/Waf-1 in a case of benign canine multicentric melanoma. Vet Pathol 1998;35:94-101. (Pubitemid 129543197)
38. Harris LJ, Skaletsky E, McPherson A. Crystallographic structure of an intact IgG1 monoclonal antibody. J Mol Biol 1998;275:861-72. (Pubitemid 28077701)
39. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 1993;234:779-815. (Pubitemid 24007801)
40. Shen MY, Sali A. Statistical potential for assessment and prediction of protein structures. Protein Sci 2006;15:2507-24. (Pubitemid 44771688)
41. Laskowski RA, Rullmannn JA, MacArthur MW, Kaptein R, Thornton JM. AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J Biomol NMR 1996;8:477-86. (Pubitemid 126706801)
42. Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res 2004;32:1792-7. (Pubitemid 38832724)
43. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, et al. Clustal W and Clustal X version 2.0. Bioinformatics 2007;23:2947-8. (Pubitemid 350162903)
44. Swoboda I, Bugajska-Schretter A, Verdino P, Keller W, Sperr WR, Valent P, et al. Recombinant carp parvalbumin, the major cross-reactive fish allergen: a tool for diagnosis and therapy of fish allergy. J Immunol 2002;168:4576-84. (Pubitemid 34441363)
45. Starkl P, Felix F, Krishnamurthy D, Stremnitzer C, Roth-Walter F, Prickett SR, et al. An unfolded variant of the major peanut allergen Ara h 2 with decreased anaphylactic potential. Clin Exp Allergy 2012;42:1801-12.
46. Bracher M, Gould HJ, Sutton BJ, Dombrowicz D, Karagiannis SN. Three-colour flow cytometric method to measure antibody-dependent tumour cell killing by cytotoxicity and phagocytosis. J Immunol Methods 2007;323:160-71. (Pubitemid 46900832)
47. Warr GW, Hart IR. Binding of canine IgM and IgG to protein A of Staphylococcus aureus: a simple method for the isolation of canine immunoglobulins from serum and the lymphocyte surface. Am J Vet Res 1979;40:922-6.
48. Yamamoto S, Omura M, Hirata H. Isolation of porcine, canine and feline IgG by affinity chromatography using protein A. Vet Immunol Immunopathol 1985;9:195-200. (Pubitemid 15009756)
49. Scott MA, Davis JM, Schwartz KA. Staphylococcal protein A binding to canine IgG and IgM. Vet Immunol Immunopathol 1997;59:205-12. (Pubitemid 28072821)
50. Kim GP, Grothey A. Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab. Biologics 2008;2:223-8.
51. Marconato L, Gelain ME, Comazzi S. The dog as a possible animal model for human non-Hodgkin lymphoma: a review. Hematol Oncol 2013;31:1-9.
52. Owen LN. A comparative study of canine and human breast cancer. Invest Cell Pathol 1979;2:257-75. (Pubitemid 10172451)
53. Lindblad-Toh K, Wade CM, Mikkelsen TS, Karlsson EK, Jaffe DB, Kamal M, et al. Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature 2005;438:803-19. (Pubitemid 41753059)
54. Cooley DM, Waters DJ. Skeletal metastasis as the initial clinical manifestation of metastatic carcinoma in 19 dogs. J Vet Intern Med 1998;12:288-93.
55. Jaillardon L, Barthelemy A, Goy-Thollot I, Pouzot-Nevoret C, Fournel-Fleury C. Mammary gland carcinoma in a dog with peripheral blood and bone marrow involvement associated with disseminated intravascular coagulation. Vet Clin Pathol 2012;41:261-5.
56. Jubala CM, Wojcieszyn JW, Valli VE, Getzy DM, Fosmire SP, Coffey D, et al. CD20 expression in normal canine B cells and in canine non-Hodgkin lymphoma. Vet Pathol 2005;42:468-76. (Pubitemid 40993857)
57. Gama A, Gartner F, Alves A, Schmitt F. Immunohistochemical expression of epidermal growth factor receptor (EGFR) in canine mammary tissues. Res Vet Sci 2009;87:432-7.
58. Fukuoka H, Cooper O, Ben-Shlomo A, Mamelak A, Ren SG, Bruyette D, et al. EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J Clin Invest 2011;121:4712-21.
59. Sabattini S, Mancini FR, Marconato L, Bacci B, Rossi F, Vignoli M, et al. EGFR overexpression in canine primary lung cancer: pathogenetic implications and impact on survival. Vet Comp Oncol. 2012 Sep 20. [Epub ahead of print].
60. Ferreira E, Gobbi H, Saraiva BS, Cassali GD. Columnar cell lesions of the canine mammary gland: pathological features and immunophenotypic analysis. BMC Cancer 2010;10:61.
61. Millanta F, Caneschi V, Ressel L, Citi S, Poli A. Expression of vascular endothelial growth factor in canine inflammatory and non-inflammatory mammary carcinoma. J Comp Pathol 2010;142:36-42.
62. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005;7:301-11. (Pubitemid 40544648)
63. Tang L, Sampson C, Dreitz MJ, McCall C. Cloning and characterization of cDNAs encoding four different canine immunoglobulin gamma chains. Vet Immunol Immunopathol 2001;80:259-70. (Pubitemid 32655453)
64. Bruggemann M, Williams GT, Bindon CI, Clark MR, Walker MR, Jefferis R, et al. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 1987;166:1351-61. (Pubitemid 18051427)
65. Reichert JM, Wenger JB. Development trends for new cancer therapeutics and vaccines. Drug Discov Today 2008;13:30-7.
66. Peng ZK, Simons FE, Becker AB. Differential binding properties of protein A and protein G for dog immunoglobulins. J Immunol Methods 1991;145:255-8.
67. Buffet W, Geboes KP, Dehertogh G, Geboes K. EGFR-immunohistochemistry in colorectal cancer and non-small cell lung cancer: comparison of 3 commercially available EGFR-antibodies. Acta Gastroenterol Belg 2008;71:213-8. (Pubitemid 351976344)
68. Lee HJ, Xu X, Choe G, Chung DH, Seo JW, Lee JH, et al. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: comparison of four commercially available antibodies by immunohistochemistry and fluorescence in situ hybridization study. Lung Cancer 2010;68:375-82.
69. Petricevic B, Laengle J, Singer J, Sachet M, Fazekas J, Steger G, et al. Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients. J Transl Med 2013;11:307.